Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

A Dual Action Approach to Treating MASH

29:37
 
Share
 

Manage episode 508164183 series 3323646
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the United States, and its incidence continues to rise. In fact, MASH is now among the leading causes of liver transplantation in the United States. 89bio is developing an experimental therapy to target multiple disease mechanisms of the condition. We spoke to Rohan Palekar, CEO of 89bio, about what’s driving the prevalence of MASH, the limits of existing medicines, and how its experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease. Since recording this interview, Roche announced it would acquire 89bio for $14.50 a share and a contingent value right of $6 per share for up to a total of $3.5 billion.

  continue reading

583 episodes

Artwork
iconShare
 
Manage episode 508164183 series 3323646
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

MASH, a chronic and progressive form of fatty liver disease that until recently was known as NASH, affects millions of people in the United States, and its incidence continues to rise. In fact, MASH is now among the leading causes of liver transplantation in the United States. 89bio is developing an experimental therapy to target multiple disease mechanisms of the condition. We spoke to Rohan Palekar, CEO of 89bio, about what’s driving the prevalence of MASH, the limits of existing medicines, and how its experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease. Since recording this interview, Roche announced it would acquire 89bio for $14.50 a share and a contingent value right of $6 per share for up to a total of $3.5 billion.

  continue reading

583 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play